{"id":"W4321612529","doi":"10.1001/jamaoncol.2022.7770","title":"Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval","year":2023,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Astellas Pharma; Seagen; Flatiron Health; Emerson Collective; National Palliative Care Research Center; Eisai; National Comprehensive Cancer Network; F. Hoffmann-La Roche; University of Pennsylvania; Myriad Genetics; Prostate Cancer Foundation; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Cancer Care Ontario; Pfizer; Amgen; Conquer Cancer Foundation","keywords":"Medicine; Food and drug administration; Cancer drugs; Drug approval; Drug; Drug administration; Administration (probate law); Cancer; Pharmacology; Intensive care medicine; Oncology; Family medicine; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00392802,0.0001755682,0.000892332,0.000311666,0.00008213097,0.00005551637,0.0001548904,0.0002224851,0.000339601],"category_scores_gemma":[0.0004278709,0.0001993672,0.00004826689,0.0003672804,0.00008993584,0.000250959,0.00005756743,0.0001616074,0.0003084139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003427919,"about_ca_system_score_gemma":0.00039476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001101192,"about_ca_topic_score_gemma":0.005966334,"domain_scores_codex":[0.996941,0.0001613335,0.001923354,0.0005241155,0.00008293973,0.0003672342],"domain_scores_gemma":[0.9977469,0.0005550955,0.001065913,0.0003032918,0.0001330205,0.0001957567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001696073,0.0004999331,0.8504465,0.0015413,0.0006421347,0.00002483365,0.02784592,0.001925189,0.00009663466,0.04550723,0.05851382,0.01126048],"study_design_scores_gemma":[0.004058588,0.002556226,0.8309781,0.0001229796,0.00002865712,0.00001527705,0.002798947,0.001485113,0.0002142546,0.002342147,0.1548555,0.0005442454],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9494123,0.0004061176,0.00005268814,0.04642891,0.0003580281,0.0008319655,0.0005053091,0.00005175772,0.001952923],"genre_scores_gemma":[0.9876564,0.00009640224,0.0007260113,0.009602171,0.0002620036,0.0005933497,0.00005797771,0.0000306747,0.0009750355],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09634167,"threshold_uncertainty_score":0.8129958,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2842487831802643,"score_gpt":0.43793605879495,"score_spread":0.1536872756146857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}